Instituto Do Cancer Do Estado De São Paulo

This study is testing if a shorter, one-year course of pembrolizumab immunotherapy works as well as the standard two-year course for people with advanced melanoma that has spread or returned. It aims to make this effective treatment more accessible and affordable within Brazil's …

This study is testing a new way of giving an existing liver cancer drug called regorafenib. The goal is to see if starting with a lower dose and slowly increasing it over the first two months helps patients better tolerate the treatment and stay on it longer. It involves 28 peopl…